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ABSTRACT
The European Medicines Agency has approved a multicomponent serogroup B meningococcal vaccine
(Bexsero) for use in individuals of 2 months of age and older. A cost-effectiveness analysis (CEA) from the
societal and Italian National Health Service perspectives was performed in order to evaluate the impact of
vaccinating Italian infants less than 1 y of age with Bexsero, as opposed to non-vaccination. The analysis
was carried out by means of Excel Version 2011 and the TreeAge Pro software Version 2012. Two basal
scenarios that differed in terms of disease incidence (ofﬁcial and estimated data to correct for
underreporting) were considered. In the basal scenarios, we considered a primary vaccination cycle with 4
doses (at 2, 4, 6 and 12 months of age) and 1 booster dose at the age of 11 y, the societal perspective and
no cost for death. Sensitivity analyses were carried out in which crucial variables were changed over
probable ranges. In Italy, on the basis of ofﬁcial data on disease incidence, vaccination with Bexsero
could prevent 82.97 cases and 5.61 deaths in each birth cohort, while these ﬁgures proved to be three
times higher on considering the estimated incidence. The results of the CEA showed that the Incremental
Cost Effectiveness Ratio (ICER) per QALY was €109,762 in the basal scenario if ofﬁcial data on disease
incidence are considered and €26,599 if estimated data are considered. The tornado diagram indicated
that the most inﬂuential factor on ICER was the incidence of disease. The probability of sequelae, the cost
of the vaccine and vaccine effectiveness also had an impact. Our results suggest that vaccinating infants in
Italy with Bexsero has the ability to signiﬁcantly reduce meningococcal disease and, if the probable
underestimation of disease incidence is considered, routine vaccination is advisable.
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Introduction
Invasive disease caused by Neisseria meningitidis (Nm) is a
serious public health problem and has a heavy economic
impact.1,2 The incidence of invasive disease is highly vari-
able according to geographical area.3 In Europe, since the
introduction of massive meningococcal serogroup C vacci-
nation, serogroup B has become the main causative agent
of meningococcal disease, and is associated with high rates
of mortality and disability; children under 1 y of age are
mainly affected.4,5 In Italy, about 60% of typed cases of
meningococcal invasive disease are now caused by Neisseria
meningitidis B (NmB).6-8
In the past, many attempts to produce an effective vaccine
against NmB were made in various parts of the world. How-
ever, owing to the great similarity between NmB capsular poly-
saccharide and human neural components,9 preparation of an
effective vaccine has proved very difﬁcult.4,5 Consequently,
research has focused on sub-capsular components, particularly
on the antigens of the outer membrane vesicles (OMVs). Vac-
cines based on OMVs have been developed and have proved to
be efﬁcacious in Norway,10 Cuba,11 Brazil,12 Chile,13 and New
Zealand.14 These experiences have shown that, because OMV
vaccines are strictly strain-speciﬁc, they are useful in epidemics
sustained by the same strain as that contained in the vaccine;
this is logical, given the great variability of the outer membrane
proteins.15
A new multicomponent vaccine (Bexsero), produced by
means of reverse vaccinology, has now gained marketing autho-
risation in Europe,16 Canada,17 Australia18 and the US.19 We
therefore felt that it would be useful to carry out a cost-effec-
tiveness analysis (CEA) on the possible use of Bexsero in the
Italian epidemiological scenario.
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Results
Introducing vaccination with Bexsero in Italian infants could
prevent 82.97 cases and 5.61 deaths in each birth cohort, con-
sidering ofﬁcial data on disease incidence (0.23 per 100,000
subjects),8 and 248.91 cases and 16.83 deaths considering esti-
mated data on disease incidence (0.69 per 100,000).20
Table 1 shows the results of CEA. As can be seen, the Incre-
mental Cost Effectiveness Ratios (ICERs) per QALY were
€109,762 for basal scenario 1 and €26,599 for basal scenario 5.
The ICERs were €120,990 and €37,827 from the National
Health Service (NHS) perspective, considering the ofﬁcial and
estimated data on disease incidence, respectively.
With regard to the 8 scenarios developed, the 4 scenarios
that considered estimated data on disease incidence proved
cost-effective at a threshold value of €50,000 (Table 1).
The Incremental Cost-Effectiveness (ICE) ellipse scatter-
plots (Fig. 1) showed that, at a threshold value of €50,000
per QALY, the introduction of vaccination had 0.04% of
probability of being cost-effective in scenario 1 and 97.08%
of probability of being cost-effective in scenario 5. These
ﬁndings were conﬁrmed by the cost-effectiveness acceptabil-
ity curves (Fig. 2).
One-way sensitivity analyses were developed on considering
the inﬂuence of disease incidence on the ICER for the vaccina-
tion strategy (Fig. 3). Further one-way sensitivity analyses were
developed on considering the inﬂuence of vaccine effectiveness
on the ICER for the vaccination strategy (Fig. 4).
Figure 5 illustrates the results yielded by Tornado analyses
on considering the ICER. The tornado diagrams indicate that
the most inﬂuential factor is disease incidence. The probability
of sequelae, the cost of the vaccine and vaccine effectiveness
also have an impact.
Discussion
When a new vaccine, such as Bexsero, becomes available,
decision-makers must decide whether to introduce it into the
National Immunization Program (NIP) or to wait until more
evidence has been obtained (cost–effectiveness, etc.) or until
conditions change (price, ﬁnancial resources, supply, program
strength, etc.). World Health Organization (WHO) guidelines
on this issue21 suggest considering: public health priorities (dis-
ease burden; other inventions; efﬁcacy, quality and safety of the
vaccine; and economic and ﬁnancial issues), the available of the
vaccine on the market, and the availability of supply. In this
regard, cost-effectiveness studies are helpful to decision-
makers.
Our study showed that vaccinating infants in Italy with
Bexsero has the ability to signiﬁcantly reduce meningococcal
disease, and that the vaccine program could be cost-effective if
the possible underestimation of disease incidence is considered.
It is important to highlight that the mathematical and eco-
nomic models applied to the transmission and prevention of
infectious diseases necessarily adopt a reductionist approach.22
Table 1. Results of CEA analysis broken down by different scenarios.
Scenario Perspective Cost of death Number of vaccine doses Disease incidence ICER per QALY (€)
1 Social 0 5 ofﬁcial data 109,762
2 Social SHC 5 ofﬁcial data 109,191
3 Social WTP 5 ofﬁcial data 104,657
4 NHS 0 5 ofﬁcial data 120,990
5 Social 0 5 estimated data 26,599
6 Social SHC 5 estimated data 26,029
7 Social WTP 5 estimated data 21,494
8 NHS 0 5 estimated data 37,827
Figure 1. Incremental Cost-Effectiveness (ICE) ellipse scatterplots showing the distribution of values of incremental costs and incremental effectiveness resulting from the
Monte Carlo simulation. Points below the threshold value indicate cost-effectiveness.
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In the case of meningococcal disease, this is particularly true
with regard to the possible underestimation of disease inci-
dence and the evaluation of possible sequelae and their costs.
Regarding the underestimation of disease incidence, although
the Italian system of surveillance of invasive bacterial diseases
is well established and well structured, it does have limitations.
For instance, in most cases when the patient is taken to hospi-
tal, antibiotic therapy has already been started. Moreover, as
the Regional Centers do not always promptly dispatch isolated
strains to the National Institute of Health (ISS) for typing, a
certain proportion of isolated strains cannot be typed. Finally,
many fulminant cases are not recognizable as such according
to the evidence requested by the WHO.23 Indeed, 2 recent Ital-
ian studies demonstrated that in Italy the real incidence of bac-
terial invasive diseases is greatly underestimated.20,24 Azzari
et al.20 reported that culture has so far been the most fre-
quently used technique for meningococcal surveillance in Italy.
However, bacterial culture leads to considerable underestima-
tion of the number of cases. In that study, the authors
compared the culture method with the molecular method and
found that the sensitivity of culture was less than one third of
that of the molecular method. Furthermore, culture displayed
lower sensitivity than the molecular method when patients had
been treated with antibiotics.20 Therefore, on the basis of the
results of the study by Azzari et al.20 and in order to limit the
possible underestimation of disease incidence, we implemented
option 2 considering an annual estimated disease incidence of
0.69 per 100,000 (scenarios 5, 6, 7 and 8). This issue is very
important as disease incidence is the major factor inﬂuencing
ICER, as highlighted by our results and also by previous eco-
nomic evaluations.25-27
Another key issue that affects ICER is the estimation of
sequelae. Indeed, many of the studies in the medical literature
have not considered all relevant sequelae. Moreover, as it is not
rare for survivors to suffer multiple sequelae, it is very difﬁcult
to evaluate their frequency and combinations. Therefore, we
tried to limit this factor of underestimation (probability of
long-term sequelae) as far as possible. We believe that this
Figure 2. Cost-effectiveness acceptability curves (“vaccinate” and “do not vaccinate”). The ﬁgures show the probability of being cost-effective on varying the threshold
value.
Figure 3. Impact of average annual incidence (per 100,000) of serogroup B invasive disease on the ICER (one-way sensitivity analysis). The probability of disease is per
person.
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approach is one of the strengths of our study. Indeed, cost-
effectiveness studies often neglect the issue of underestimation
and tend to be very conservative.25-29 Our study indicated that
the parameter “probability of sequelae” was one of the parame-
ters impacting ICER.
An HTA analysis30 performed in Italy estimated that
introducing Bexsero into the infant immunization program
would be cost-effective from the social perspective under
speciﬁc assumptions, in particular on considering discount
rates lower than 3% (ICER D €44.872 considering discount
rate 1.5% for outcomes and 3% for costs; ICER D €26,806
considering discount rate 1.5% both for outcomes and costs).
Furthermore, a recent Italian cost-effectiveness analysis
found that routine infant immunization with Bexsero
would not be cost-effective with an ICER of > 350,000
€/QALY.25 In this latter study, Tirani et al.25 considered a 3-
dose vaccine immunization schedule at 2, 3 and 4 months
followed by 1 catch-up dose between 12 and 23 months, a
cost per vaccine dose of €67, vaccine efﬁcacy of 75% and 3-y
duration of protection; however, their analysis only consid-
ered the direct costs associated with meningococcal invasive
disease (NHS perspective). Notably, it is difﬁcult to compare
the results of these study25,30 with our ﬁndings, owing to the
different values of the parameters used.
So far, some economic analyses of the introduction of vacci-
nation against NmB have been published in developed coun-
tries.26-29 Pouwels et al. concluded that: at the current low level
of disease incidence, the introduction of routine infant vaccina-
tion (4-dose schedule) is unlikely to be cost-effective in the
Netherlands28; Tu et al. also reported the same conclusions
with regard to the Canadian setting.26 Christensen et al.
claimed that the new MenB vaccine could substantially reduce
the disease in England and be cost-effective if competitively
priced, particularly if the vaccine can prevent carriage as well as
disease.27,29
It is important to consider that some economic studies on
vaccinations are performed only from the perspective of the
third-party payer (usually the NHS).25,26 However, meningo-
coccal disease generates very high indirect costs, such as, for
instance, the loss of productivity of patients and their parents,
and the need for special education for the subjects affected by
severe complications (for example mental retardation, cognitive
Figure 5. Tornado diagrams evaluating the inﬂuence of each parameter of the model on ICER.
Figure 4. Impact of vaccine effectiveness on the ICER (one-way sensitivity analysis).
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problems, hearing loss and severe speech or communication
problems, etc.). We therefore considered the societal perspec-
tive as the basal scenario, precisely in order to provide a com-
plete picture of the general costs of the disease. Indeed, WHO
recommends to evaluating the widest perspective.31
The cost and effectiveness of the vaccine and the duration of
protection may also play an important role in inﬂuencing
ICER. With regard to vaccine effectiveness, we considered the
results of clinical trials on vaccine efﬁcacy and the results of the
study by Vogel et al.32 on predicted strain coverage. Their study
assessed the predicted strain coverage by using the Meningo-
coccal Antigen Typing System (MATS) method, which a very
recent study considered to be a conservative predictor of strain
coverage by Bexsero in infants. Indeed, the authors demon-
strated that, although MATS and hSBA yielded signiﬁcantly
associated results, hSBA more often also revealed protection
against strains which did not prove positive on MATS.33 Strain
coverage could therefore be higher.
With regard to the duration of protection, complete informa-
tion is not yet available, as the vaccine is recent; the duration of
protection can therefore only be hypothesized. We assumed a
10-y duration of full vaccine protection26 and subsequent waning
of protection, whereby vaccination would only directly prevent
one-quarter of cases over the lifetime of a vaccinated birth
cohort.34 It must be noted that the majority of cases occur in the
ﬁrst years of life,4,5,20 followed by a secondary lower peak in ado-
lescents and young adults.35 Given the epidemiological trend of
meningococcal disease, an adolescent booster dose may be useful
in order to prevent the cases that occur during this period of life.
This strategy has also been advocated by other researchers.34 Our
model therefore considered a booster dose at 11 y of age.
Like all pharmaco-economic analyses, the present study
has limitations because the models are a simpliﬁcation of the
real world setting. Firstly, as only limited data are available on
some parameters, we had to make certain assumptions, partic-
ularly with regard to the duration of protection conferred by
the vaccine. For what concerns sequelae-related costs, we had
to use data from studies conducted outside Italy, as no Italian
study reports the data needed in order to carry out a phar-
maco-economic analysis. We assumed that the life expectancy
of subjects affected by disease who survive with sequelae was
the same as that of unaffected subjects (except for the sequela
“renal failure”). This is not completely true, though the differ-
ences seem to be small.29,36 The whole cohort (531,372 indi-
viduals) experienced a naturally occurring, age-related decline
in quality of life.
We implemented a static model and did not consider herd
immunity. However, it is probable that Bexsero would have
an impact on carriage; this issue was investigated in a very
recent study.37 Nevertheless, herd protection is more likely to
occur if a booster dose is administered in adolescence, as car-
riage is particularly high in teenagers.28,38,39
In conclusion, our results suggest that vaccinating infants in
Italy with Bexsero has the ability to signiﬁcantly reduce
meningococcal disease and, if the probable underestimation of
disease incidence is considered, routine vaccination is
advisable.
Surveillance after vaccine implementation will be crucial in
order to evaluate some parameters, as the true effectiveness of
the vaccine and the duration of protection are not yet fully
known. Furthermore, potential beneﬁts due to cross-protection
against non-B serogroups40-42 and the vaccine ability to induce
herd protection will need to be assessed.
Materials and methods
Design
A static cohort-simulation model was developed. In order
to evaluate the vaccination strategy, a decisional-tree
model was created by means of TreeAge Pro software
(Microsoft Inc., Redmond, WA; 1988–2012 TreeAge Soft-
ware, Inc.). Figure 6 shows a simpliﬁed version of the
decisional tree; the complete decisional tree is reported in
Electronic Supplementary Material A1. Our decisional tree
deﬁned two strategies: vaccinating or not vaccinating
infants less than 1 y of age. A cohort of 531,372 individu-
als was used, corresponding to the number of children less
than 1 y of age who were resident in Italy at the 2012
census.43
The cost-effectiveness study was modeled on routine immu-
nization with 4 doses (at 2, 4, 6 and 12 months of age) of
Bexsero (primary cycle) and 1 booster dose at the age of 11 y
(Table 2).
The “Vaccination” branch of the tree (Fig. 6) was divided
into two branches, according to whether or not parents chose
to have their children vaccinated (compliance node). Compli-
ance inﬂuences the coverage rate. We considered a coverage
rate of 90% as the base case. In the sensitivity analysis, a range
of 50–100% was considered.
Vaccinated children may or may not be protected, depending
on the predicted effectiveness of the vaccine (see sub-section
Table 2. Scenarios evaluated.
Scenario Perspective Cost of death
Number of vaccine doses
[Primary cycle (2, 4, 6 and 12 months of age)
and booster dose at 11 y] Disease incidence
1 Social 0 5 ofﬁcial data
2 Social SHC 5 ofﬁcial data
3 Social WTP 5 ofﬁcial data
4 NHS 0 5 ofﬁcial data
5 Social 0 5 Estimated data
6 Social SHC 5 Estimated data
7 Social WTP 5 Estimated data
8 NHS 0 5 Estimated data
Basal scenarios.
HUMAN VACCINES & IMMUNOTHERAPEUTICS 5
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 E
xe
ter
] a
t 0
1:0
6 1
1 M
ay
 20
16
 
“Vaccine efﬁcacy, predicted effectiveness and duration of protec-
tion”). Unprotected infants were considered to be susceptible; their
probability of acquiring meningococcal disease was therefore
deemed to be the same as that of unvaccinated subjects (“Not Vac-
cinated” branch).
We assumed that protectionwouldwane over time (see sub-sec-
tion “Vaccine efﬁcacy, predicted effectiveness and duration of pro-
tection”). Protection began after 2 doses of the vaccine.27,44
Unvaccinated infants (“Not Vaccinated” branch) were
regarded as having the possibility to live their whole lives with-
out contracting the disease. If, however, they contracted the dis-
ease, 2 outcomes were possible: death or survival. Survivors
were then divided into 2 different categories: without or with
sequelae. We assumed that any subjects who had had the dis-
ease would no longer be susceptible (as repeat invasive disease
is rare and is associated with individuals with immune deﬁcien-
cies and anatomical defects27).
We considered the acute-phase and lifetime consequen-
ces of invasive disease caused by NmB (direct and indirect
costs). For each case, the burden of meningococcal disease
was assessed on the basis of age-adjusted life expectancy on
disease acquisition. We considered an average life expec-
tancy of 82.03 y as reported by the Italian National Statis-
tics Institute (ISTAT).43
We calculated the costs of the vaccination strategy,
including the costs due to the treatment of adverse events
caused by vaccination. On the basis of the difference
between the costs of both strategies (vaccination and no
vaccination), the potential beneﬁts of the new vaccine were
evaluated. The study was conducted from the perspectives
of both the third-party payer [National Health Service
(NHS)] and society. In the societal perspective, two options
were considered: no cost for death and cost for death.
All costs were adjusted to the value of € in 2013,45 and were
discounted as indicated by Italian guidelines (discount rate of
3% both for costs and utilities).46,47 In the sensitivity analysis, a
range of 0 – 8% was considered.
Our model considered 2 options on the basis of 2 different
probabilities of disease, as reported in the sub-section “disease
incidence.”7,20
Eight scenarios were evaluated (Table 2), the basal scenarios
being scenarios 1 and 5. Scenario 1 considered the following
parameters: social perspective, no cost of death, primary vacci-
nation cycle with 4 doses (2, 4, 6 and 12 months of age) and
booster dose at the age of 11 y and ofﬁcial data on disease inci-
dence. Scenario 5 considered the following parameters: social
perspective, no cost of death, primary vaccination cycle with 4
doses (2, 4, 6 and 12 months of age) and booster dose at the age
of 11 y and estimated data on disease incidence.
Disease incidence
Disease-incidence estimates were based on the special Invasive Dis-
eases Surveillance System (MIB) of the ItalianMinistry of Health.48
In Italy, it is mandatory to notify the MIB of laboratory-conﬁrmed
cases of invasive disease caused by Nm. Cases are reported to the
Local Health Unit (LHU), which communicates the data to the
Regional and National Authorities. Concurrently, all hospitals
should report any conﬁrmed or suspected cases of bacterial inva-
sive disease to the LHU. Cases are described on individual case-
report forms, which include information on the clinical status,
microbiological results and vaccination status.49
All labs that isolate a strain of Nm are requested to send the
isolate to the National Reference labs, based at the National
Institute of Health (ISS), for conﬁrmation, serotyping and
molecular typing. In the reports of the ISS, cases are subdivided
into 7 age-classes: 0, 1–4, 5–9, 10–14, 15–24, 25–64,
and >64 y and by Nm serogroup.7,8
Our model considered 2 options on the basis of 2 different
probabilities of disease: option 1 considered the average
Figure 6. Simpliﬁed decisional tree: meningococcal serogroup B vaccination in infants.
Legend: amputation with substantial disability, anxiety, arthritis, depression, motor deﬁcits, blindness, epilepsy or seizure, severe neurological disability, mental retarda-
tion (cognitive problems), hearing loss requiring cochlear implantation, moderate/severe bilateral hearing loss, moderate unilateral hearing loss, skin necrosis, scars,
severe speech or communication problems, renal failure, chronic migraine.
Protection was assumed to begin after the second dose of the vaccine.
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number of conﬁrmed NmB cases that occurred annually in
Italy from 2007 to 2012 (133 cases/y) (ofﬁcial data)8; option 2
considered a number of cases (399 cases/y) 3 times higher than
in option 1, on the basis of 2 recent Italian studies which dem-
onstrated that the real incidence of bacterial invasive disease in
Italy is greatly underestimated (estimated data).20,24
In option 1, we assumed an annual disease incidence of 0.23
per 100,000 subjects.8 In option 2, we assumed an annual dis-
ease incidence of 0.69 per 100,000. In the sensitivity analysis, a
range of 0.1–0.7 per 100,000 was considered.
The annual distribution of cases broken down by age is
reported in Supplementary Material (Electronic Supplementary
Material A2).
Disease consequences
Death, survival without sequelae, and survival with long-term
sequelae were the 3 outcomes considered in our model.
The case-fatality rate, broken down by age, was applied
according to the 2006 EU-IBIS report.50 In our model, we
assumed a global probability of death of 6.73%. In the sensitiv-
ity analysis, a range of 0–10% was considered.
While it is fairly easy to ﬁnd papers on the sequelae from inva-
sive bacterial disease,51 it is difﬁcult to obtain accurate measure-
ments of the long-term consequences of serogroup B disease. We
assumed that 40.2% of survivors would have at least 1 sequela, as
reported by a recent study.52 In the sensitivity analysis, a variation
of 20% was considered. The single sequelae28,53-57 considered in
our study and their frequency, are reported in Table 3. Addition-
ally, a personal communication by Magnus Gottfredsson allowed
us to evaluate the incidence of some sequelae in the cohort study
performed by this author.55 Although meningococcal disease can
cause multiple sequelae, in our study, as in other health econom-
ics studies,27 we assumed that each survivor would have only 1
sequela. Other sequelae, such as brain abscess, cranial nerve palsy,
obstructive hydrocephalus, ataxia, chronic organ damage, etc, as
deﬁned byWoods58 and by Brandtzaeg,59 were not considered.
Table 4. Health utilities of single sequelae.
Sequelae Base case Distribution
Amputation with substantial disabilitya 0.613 Uniform (0.490; 0.7356)
Anxietyb 0.687 Uniform (0.5496; 0.8244)
Arthritisc 0.690 Uniform (0.552; 0.828)
Depressionb 0.729 Uniform (0.583; 0.875)
Motor deﬁcitsd 0.830 Uniform (0.664; 0.996)
Blindnesse 0.260 Uniform (0.208; 0.312)
Epilepsy or Seizuref 0.830 Uniform (0.664; 0.996)
Severe Neurological disabilitya 0.060 Uniform (0.048; 0.072)
Mental retardation (cognitive problems mild/moderate)g 0.541 Uniform (0.4328; 0.6492)
Hearing loss requiring cochlear implantationf 0.810 Uniform (0.648; 0.972)
Moderate/severe bilateral hearing lossf 0.910 Uniform (0.728; 1)
Moderate unilateral hearing lossf 0.910 Uniform (0.728; 1)
Skin necrosish 0.900 Uniform (0.720; 1)
Scarsa 1.000 Uniform (0.8; 1)
Severe speech or communication problemsi 0.390 Uniform (0.312; 0.468)
Renal failurel 0.820 Uniform (0.656; 0.984)
Chronic migrainem 0.814 Uniform (0.6512; 0.9768)
aAccording to [53]; bAccording to [62]; cAccording to [63]; dAccording to [64]; eAccording to [65]; fAccording to [60]; gAccording to [66]; hAccording to [67]; iAccording to
[68]; lAccording to [69]; mAccording to [61].
Table 3. Probability of sequelae.
Sequelae Base case Distribution
Amputation with substantial disabilitya 0.01 Uniform (0.008; 0.012)
Anxietyb 0.068 Uniform (0.0544; 0.0816)
Arthritisb 0.025 Uniform (0.02; 0.03)
Depressionb 0.05 Uniform (0.04; 0.06)
Motor deﬁcitsc 0.019 Uniform (0.0152; 0.0228)
Blindnessa 0.004 Uniform (0.0032; 0.0048)
Epilepsy or Seizurea 0.02 Uniform (0.016; 0.024)
Severe Neurological disabilityd 0.021 Uniform (0.0168; 0.0252)
Mental retardation (cognitive problems)b,e 0.254 Uniform (0.196; 0.312)
Hearing loss requiring cochlear implantationa 0.02 Uniform (0.016–0.024)
Moderate/severe bilateral hearing lossa 0.05 Uniform (0.04; 0.06)
Moderate unilateral hearing lossa 0.05 Uniform (0.04; 0.06)
Skin necrosisb 0.015 Uniform (0.012; 0.018)
Scarsf 0.03 Uniform (0.024; 0.036)
Severe speech or communication problemsa 0.037 Uniform (0.0296; 0.0444)
Renal failureb 0.019 Uniform (0.0152; 0.0228)
Chronic migraineb 0.10 Uniform (0.08; 0.12)
aAccording to [56]; bAccording to [55]; cAccording to [28]; dAccording to [53]; eAccording to [57]; fAccording to [54].
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Quality of life
Our model also considered the impairment of the quality of life
(QoL) of survivors with long-term sequelae. This assessment
was necessary in order to evaluate the permanent consequences
for health status. Furthermore, because few data are available
on the QoL of survivors of meningococcal disease,60 we some-
times used QoL evaluations for sequelae or pathologies similar
to those caused by meningitis; for instance, for chronic
migraine, the results reported by Xu et al. were used.61
Table 4 shows the health utilities broken down by
sequelae.53,60-69
Vaccine efﬁcacy, predicted effectiveness and duration
of protection
In clinical trials conducted with rMenBCOMV (Bexsero),
vaccine efﬁcacy has been studied by means of the serum bacte-
ricidal antibody assay by human complement (hSBA).44,70-72
In studies involving infants, adolescents and young
adults, the 4CMenB vaccine has been shown to induce
robust bactericidal antibodies against strains expressing the
vaccine antigens.73 Therefore, on the basis of the results of
clinical trials,74,75 and considering another economic evalua-
tion,29 we assumed that vaccinated subjects would have
95% protection against disease. Furthermore, a study esti-
mating the strain coverage of Bexsero predicted strain cov-
erage in Italy to be 87%.32 Therefore, we used this estimate
in our model. In the sensitivity analysis, a variation of 20%
was considered both for vaccine efﬁcacy and for predicted
strain coverage.
Data on the duration of protection conferred by Bexsero
are incomplete. Considering the basic assumptions of immu-
nology,76 the results obtained in clinical trials of Bexsero77
and an economic evaluation conducted in Canada,26 we
assumed 10-y duration of full vaccine protection and subse-
quent waning of protection, whereby vaccination would only
directly prevent one-quarter of cases over the lifetime of a vac-
cinated birth cohort.34 Furthermore, clinical trials have demon-
strated the ability of Bexsero to induce immunological
memory.35,74,75,77 If immunological memory is induced by the
vaccine, the natural MenB infection could acts as booster and
help to maintain long-term protection.
Given the epidemiological trend of meningococcal disease,
an adolescent booster dose may be useful in order to prevent
the cases that occur during this period of life. Our model there-
fore considered a booster dose at 11 y of age.
Costs associated with the disease
The study was conducted from the perspectives of both the Ital-
ian NHS and society. All costs were measured in € at January
2013 values, with previous years being adjusted to January
2013 levels.45 To determine the total cost of meningococcal
Table 5. Acute phase of disease: costs (no discount rate) were measured in € at
January 2013 values and were referred to 1 case.
Parameter Base case Distribution
Medical care: cost of hospitalization per casea 7,900 Gamma (25; 316)
Public Health Responseb 3,223 Gamma (25; 128)
Lost productivity of parent or relativesc 870 Gamma (25; 35)
Lost productivity of patientc 1,426 Gamma (25; 57)
aAccording to [78]; bAssumed based upon [53]; cAccording to [8,79].
Table 6. Meningococcal sequelae. Costs (no discount rate) were measured in € at January 2013 values.
Parameters Base Case Distribution
Annual direct costs (1 case)
Amputation with substantial disabilitya 7,339 Gamma (25; 293.6)
Anxietyb 1,146 Gamma (25; 45.8)
Arthritis(1-y cost)c 1,184 Gamma (25; 47.4)
Depressiond 3,192 Gamma (25; 127.7)
Motor deﬁcitse 7,682 Gamma (25; 307.3)
Blindnessf 4,076 Gamma (25; 163.0)
Epilepsy or seizureg 2,272 Gamma (25; 90.9)
Severe neurological disabilityh 94,880 Gamma (25; 3795.0)
Mental retardation (cognitive problems)e 7,507 Gamma (25; 300.3)
Hearing loss requiring cochlear implantationa 6,327 Gamma (25; 253.1)
Moderate/severe bilateral/unilateral hearing lossa 3,163 Gamma (25; 126.5)
Skin necrosisa 1,066 Gamma (25; 42.6)
Scarsh 533 Gamma (25; 21.3)
Severe speech or communication problemsi 9,796 Gamma (25; 391.8)
Renal failurel 56,126 Gamma (25; 2245.0)
Chronic migrainem 892 Gamma (25; 35.7)
Annual indirect costs (1 case)
Special case educationh 14,566 Gamma (25; 582.2)
Lost productivity of parent^n 24,500 Gamma (25; 980.0)
Lost productivity of patiento 24,500 Gamma (25; 980.0)
aAccording to [53]; bAccording to [80]; cAccording to [81]; dAccording to [82]; eAccording to [83]; fAccording to [84]; gAccording to [85,86]; hAccording to [87]; iAccording
to [30]; lAccording to [88]; mAccording to [89]; nAccording to [90,91,92]; oAccording to [90,92,93].
Applied to: motor deﬁcits, blindness, epilepsy or seizure, mental retardation (cognitive problems), hearing loss and severe speech or communication problems.
A^pplied to: mental retardation (cognitive problems), severe neurological disability, severe speech or communication problems, epilepsy, blindness, motor deﬁcit, severe
amputations and hearing loss.
Applied to: severe amputations, anxiety, depression, motor deﬁcit, blindness, epilepsy or seizure, severe neurological disability, mental retardation (cognitive problems),
Hearing loss requiring cochlear implantation, Moderate/severe bilateral/unilateral hearing loss, renal failure, severe speech or communication problems.
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disease, we considered the following categories of costs: costs
related to the acute phase of disease (direct and indirect
costs)8,53,78,79 (Table 5), costs related to meningococcal sequelae
(direct and indirect costs)30,53,80-93 (Table 6) and the social costs
of death94 (Table 7).
Costs related to the acute phase of disease
The costs of the acute phase of disease were applied to all cases
and are shown in Table 5.
The direct costs related to the acute phase of meningococcal
disease were those of medical care, i.e. hospitalization and pub-
lic health response. In evaluating the costs of hospitalization,
we used the cost of the Diagnosis Related Group (DRG) associ-
ated to meningococcal disease.78 We calculated the cost of the
public health response to a case of meningococcal disease by
considering the average number of contacts that required che-
moprophylaxis treatment, the average cost of a course of che-
moprophylaxis treatment, and the average working time
devoted by public health departments to a single reported case
of meningococcal disease.53
The indirect costs were those associated with lost productiv-
ity of the patient and lost productivity of the parents or rela-
tives. With regard to costs of lost productivity of the patient, we
only considered the cases which occurred during working age
(18–64 y). We considered an average cost of €16.2 per working
hour79 for 8 hours/day (€129.6) and an average length of stay
in hospital of 11 d (€1,426).8 The costs of lost productivity of
parents or relatives were applied to all cases.8,79
Costs related to meningococcal sequelae
Survivors with sequelae constituted a subset of nonfatal cases;
these incurred sequela-speciﬁc direct medical costs. For some
complications, in addition to direct medical costs, other indirect
costs (special education, lost productivity of parents and lost pro-
ductivity of patients) were also considered. The annual direct and
indirect costs of meningococcal sequelae are shown in Table 6.
The direct costs of the sequela “amputation with substantial
disability” included both the costs of acute treatment (e.g. cost
of the amputation procedure) and lifetime medical costs (e.g.,
maintenance of prosthetics, rehabilitation etc).53 The direct
costs of the sequela “hearing loss requiring cochlear implanta-
tion” included not only the costs of the cochlear implant, but
also that of its implantation and lifetime maintenance.53 With
regard to severe neurological disability, our estimate of the
direct costs also considered the costs of long-term institutional
care,87 while for the sequela “arthritis,” we only considered the
medical costs for 1 y, as this complication is usually resolved by
short-term therapy.81,95 Finally, our estimate of the costs of the
sequela “renal failure” took into account the permanent organ
damage that can lead to kidney transplantation or dialysis,
assuming a life expectancy of 5 y.88
With regard to indirect costs, we considered the costs of
special education87 for the following sequelae: motor deﬁ-
cits, blindness, epilepsy or seizure, mental retardation (cog-
nitive problems), hearing loss and severe speech or
communication problems. These costs were calculated by
determining the age-speciﬁc additional costs per child per
year in comparison with regular education, and were
applied to subjects younger than 17 y of age, as education
is compulsory up to that age in Italy. Moreover, some
severe sequelae require a parent to give up work in order to
assist her child. We therefore evaluated the additional cost
of lost productivity of a parent for the following severe
complications: mental retardation (cognitive problems),
severe neurological disability, severe speech or communica-
tion problems, epilepsy, blindness, motor deﬁcit, severe
amputations and hearing loss. This additional cost was con-
sidered up to the age of 17 y. In our calculations, we
Table 7. The social costs (no discount rate) of death were measured in € at January 2013 values.
Age (years) Willingness to pay (WTP)a Distribution Human Standard Capital (HSC)a Distribution
<1 1,513,985 Gamma (25; 60559.4) 81,434 Gamma (25; 3257.1)
1–4 1,594,678 Gamma (25; 63787.2) 101,143 Gamma (25; 4045.7)
5–9 1,743,967 Gamma (25; 69758.5) 148,817 Gamma (25; 5941.9)
10–14 1,924,832 Gamma (25; 76993.1) 228,391 Gamma (25; 9135.6)
15–24 2,122,126 Gamma (25; 84887.8) 368,015 Gamma (25; 14720.6)
25–64 1,260,459 Gamma (25; 50418.1) 336,674 Gamma (25; 13466.9)
>64 96,178 Gamma (25; 3847.2) 40,377 Gamma (25; 1615.1)
aAccording to [94].
Table 8. Costs associated with vaccination (€).
Direct costs
Range
Parameter Base Case Min Max Distribution
Cost of the primary cycle of vaccination (4 doses)a 200.00 100.00 300.00 Fixed
Cost of vaccine administration per doseb 5.80 – – Fixed
Cost of hospitalization for 1 anaphylactic reactionc 1,175 – – Fixed
Cost of 1 mild or moderate adverse eventd 3.40 – – Fixed
aAccording to [96]; bAccording to [97]; cAccording to [78]; dAccording to [98].
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supposed that it would be the mother who gave up her job.
The calculation of lost productivity of the mother consid-
ered the following parameters: the mean age at which
women in Italy have their ﬁrst child, the mean number of
potential working years lost by these women, the percentage
of women employed and their per capita income.90-92
To evaluate the lost productivity of patients, we estimated
the residual earning capacity of patients affected by each
sequela; this calculation was based on the disability percentages
deﬁned by Italian law93 and considered the year of disease
onset, income per capita, residual working years and unem-
ployment rate in Italy.90,92 We evaluated the additional cost of
lost productivity of a patient for the following severe complica-
tions: severe amputations, anxiety, depression, motor deﬁcit,
blindness, epilepsy or seizure, severe neurological disability,
mental retardation (cognitive problems), hearing loss requiring
cochlear implantation, moderate/severe bilateral/unilateral
hearing loss, renal failure, severe speech or communication
problems.
Social cost of death (indirect cost)
To evaluate the social cost of death, 2 approaches are usually
used: the “willingness to pay” and the “human standard capital”
methods. In our model, we calculated the social cost of death by
means of each method separately.94 The cost was computed on
considering the age of death. These values are reported in
Table 7.
Costs associated with vaccination
The costs associated with vaccination are reported in
Table 8.78,96-98
Costs of vaccine
We considered a cost of €200,00 for the primary cycle of vacci-
nation (4 doses) from the NHS and societal perspectives.96 The
cost of the booster dose at 11 y was set at €36.12 (discount rate
of 3% applied). Private sector prices were not considered. In
the sensitivity analysis, a range of costs for the primary cycle of
vaccination of €100–300 was considered.
A cost of €5.80 was attributed to the administration of each
dose of vaccine.97
Costs of vaccine-associated adverse events
Our assessment of the costs determined by mild and moderate
adverse events after vaccine administration was based on the
study by Gossger et al.99 These authors estimated a total fre-
quency of local and systemic adverse events of 30%, 26%, 28%
and 28% after the ﬁrst, second, third and fourth doses, respec-
tively.99 We considered a frequency of local and systemic
adverse events of 28% for the booster dose. As fever is the most
frequent adverse event, our evaluation considered the cost of
the most widely used antipyretic in Italy (1 box of paraceta-
mol)98 as the cost of 1 mild or moderate adverse event. In the
case of moderate adverse events, we did not consider the cost
of consultation of the pediatrician or general practitioner, as
house calls and outpatient visits are free of charge in Italy.
Regarding severe adverse events, we considered the frequency
(1 case per 719,790 doses) and costs of anaphylactic reactions
on the basis of evaluations by Christensen et al. and
AGENAS.27,78
Economic analysis
In order to evaluate the effect of introducing the meningococcal
B vaccine into the Italian immunization program, we con-
ducted a cost–effectiveness analysis (CEA). The analysis was
carried out by means of Excel Version 2011 and the TreeAge
Pro software Version 2012 (Build 12.2.3.0).
The analysis is expressed in terms of Incremental Cost Effec-
tiveness Ratio (ICER), where the denominator is the health gain
in quality-adjusted life years (QALYs) and the numerator is the
difference between the costs of the vaccination strategy and
those of a no-vaccination strategy.
Sensitivity analysis
One-way sensitivity analyses were performed in order to evalu-
ate how the uncertainty of disease incidence and vaccine effec-
tiveness can inﬂuence the ICER.
Furthermore, to obtain the best set of parameters for the
Monte Carlo simulation, a multivariate sensitivity analysis was
performed. In this analysis, we varied: disease incidence, the
probability of sequelae, the probability of death, vaccine effec-
tiveness, the probability of coverage, the cost of the vaccine,
and the cost and QALY discount rate.
The sensitivity analysis was performed for the 2 basal sce-
narios (Table 2, scenarios 1 and 5).
Monte Carlo simulation
We developed a second-order Monte Carlo simulation, which
is a 2-dimensional simulation used to propagate variability and
uncertainty separately. This procedure consists of multiple real-
izations of model parameters and iterations of input variables.
The outcome is a collection of cumulative distribution func-
tions that simultaneously display the uncertainty and variability
in the results.100 This simulation was developed by using 10,000
samples.
We then performed a CEA in which incremental costs and
health outcomes were computed and plotted on an X-Y scatter
plot. Furthermore, we drew cost-effectiveness acceptability
curves, whereby “threshold value” was plotted against the pro-
portion of runs (samples) that resulted in incremental cost-
effectiveness ratios below this threshold value.101
The Monte Carlo simulation was performed for the 2 basal
scenarios (Table 2, scenarios 1 and 5).
Tables 4, 5, 6, 7 and 8 report the range of values used in the
sensitivity analysis and Monte Carlo simulation.
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